The Drug Incubator is a Sypharma initiative.
Companies seeking to develop new biopharmaceuticals need to begin the process of ensuring reproducability in their product and their results as early as possible. This is why GMP development needs to be discussed early in the product lifecycle, and a drug master file begun to ensure quick progress to GMP product for clinical trials. The GMP status of the drug master file is of critical importance to companies seeking to licence out their technologies. Getting it right first time, means no need to duplicate costly early stage work in the scale up process.
Early consideration of these crucial components means higher and faster returns later on.
We aim to complement our current biopharmaceutical drug development capabilities with the world class facilities available in Victoria, from early stage synthesis and characterisation, to stability, process development and optimisation, GMP manufacture, lyophilisation, and clinical trials.
Sypharma is your single point of contact during the drug development process and enables you to keep all your development within world class Australian facilities from pre-clinical to phase III and beyond.
Sypharma has a proven track record of successful drug development within the international arena and now seeks to offer those services to Australian industry.